Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and
tumor cell proliferation related kinase -c-Kit kinase. In the phase Ⅲ study, patients who
failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance
were treated with anlotinib（12mg，po. qd. on day 1to14 of a 21-day cycle） or placebo, the
anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS
were 1.4 months and 6.3 months. Subgroup analysis results suggest that elderly patients may
get longer mPFS and mOS.
Therefore, the investigators envisage an open, single-arm, single-center clinical trial using
anlotinib in elderly patients with EGFR wild-type lung adenocarcinoma who refused
chemotherapy, to find if anlotinib is a better option in NSCLC second-line therapy.
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Wenzhou Medical University